ClinicalTrials.gg
RecruitingNCT07220733HEARTUpdated Oct 24, 2025

Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial

A Phase 1/2 interventional study of Self-balancing robotic exoskeleton (Atalante X) in Critical Illness, Post Operative Complication and Thoracic Surgery, sponsored by Wandercraft. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Wandercraft · Phase 1/2, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients admitted to the Intensive Care Unit (ICU) after thoracic surgery often experience complications related to immobility, such as muscle weakness, pulmonary issues, and longer recovery times. Early mobilization has been shown to improve outcomes, but its implementation is often limited by patient fragility and staff resources.

This study will test the safety and feasibility of using the Atalante X, a self-balancing exoskeleton, in the Thoracic Surgical ICU at Brigham and Women's Hospital. The exoskeleton is designed to support patients in standing and walking, even if they have limited strength or balance, thereby reducing the physical burden on healthcare staff and increasing patient mobility.

Eligible participants are adults recovering from thoracic surgery, who are debilitated (Johns Hopkins Highest Level of Mobility scale ≤ 5). Each participant will undergo up to 2-3 exoskeleton sessions per week for a maximum of 2 weeks. Sessions will be personalized, with progressive standing time and walking depending on patient tolerance.

The primary goal is to evaluate the safety of exoskeleton use, measured by adverse events such as skin lesions, cardiovascular instability, or accidental device-related issues.

The secondary goals are to evaluate:

Feasibility (ability to deliver sessions as planned, duration of standing/walking, level of assistance needed),

Usability (patient and staff satisfaction, ease of donning/doffing, staff workload), and

Preliminary effectiveness (improvement in mobility scores at discharge).

Results will provide early insights into whether robotic exoskeletons can be safely integrated into ICU rehabilitation programs after thoracic surgery.

Read the detailed description

Prolonged bed rest and immobility are common in ICU patients and are strongly associated with poor outcomes, including pulmonary complications, neuromuscular weakness, cognitive impairment, and delayed recovery. Early mobilization after thoracic surgery has been demonstrated to improve respiratory function, reduce complications, and shorten hospital stays. However, significant barriers remain, including patient instability, staffing limitations, and the complexity of mobilizing critically ill patients with multiple devices and lines.

The Atalante X exoskeleton (Wandercraft, Paris, France) is a self-balancing robotic device that enables hands-free standing and walking. Using advanced AI-based algorithms, it adjusts to patient needs and provides variable assistance. Previous clinical studies in populations with spinal cord injury and post-stroke hemiplegia have shown the device to be safe and feasible, with improvements in mobility and balance. Atalante X has obtained FDA clearance (product code PHL, Class II, 21 CFR 890.3480).

This pilot study, named HEART (Hyper Early Atalante Rehabilitation Therapy), is a prospective, single-arm, unicentric exploratory trial conducted in the Thoracic Surgical ICU at Brigham and Women's Hospital (Boston, MA).

Expected impact:

This study will provide critical early data on the integration of robotic exoskeletons into ICU rehabilitation. By supporting patient mobilization earlier and more safely, Atalante X has the potential to improve outcomes after thoracic surgery, reduce ICU length of stay, and enhance patient recovery trajectories.

02

Conditions studied

  • Critical Illness
  • Post Operative Complication
  • Thoracic Surgery

Browse trials for

Keywords

  • Thoracic Surgery
  • Postoperative Care
  • Atalante X Exoskeleton
  • Early Mobilisation
  • Intensive Care Unit (ICU)
03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's planned enrollment of 5 is below the median of 90 across 930 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Wandercraft is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Above age of 18 years old,
  • Having undergone thoracic surgery that necessitated admission in the TSICU.
  • Debilitated as defined as a JH-HLM score of 5 or less

Exclusion criteria

Exclusion Criteria:

  • Height \< 6'3 feet or weight > 220 lbs restrictions
  • Severe muscular spasticity of the lower extremities (Modified Ashworth Scale Grade 3 higher).
  • Current fractures or incomplete bone junctions in the spine, pelvis, and/or lower extremities
  • Osteoporosis or lower bone mineral density -3.5, and history(ies) of osteoporotic fracture(s).
  • Skin disorders including Stage I pressure injuries at the hip, lower limbs, and Exoskeleton contact areas, according to the National and European Pressure Ulcer Classification System (NPUAP-EPUAP).
  • Severe arthritis, acute arthritis, or synovitis after total or partial lower limb joint replacement.
  • Myocardial infarction or angina or ischemic heart disease within the last 6 months.
  • Uncorrectable leg length discrepancy over 2 cm when using additional correction tools.
  • III-IV spine scoliotic deformity.
  • Amputations and lower limb prostheses.
  • Pregnancy
  • Adults who lack the capacity to provide
  • Cardiovascular instability as indicated by:
  • Presence of unstable ventricular or atrial arrhythmias
  • HR \< 40 or HR > 140
  • Lactate > 4.0 mmol/L
  • On moderate-high dose vasopressors/inotropes
  • Currently on VA ECMO
  • Respiratory instability as indicated by:
  • FiO2 > 0.6
  • PEEP > 12 cm H2O
  • RR > 35 bpm
  • Currently on VV-ECMO
  • Unable to follow commands
  • Has bed rest orders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Early mobilization with the Atalante X self-balancing exoskeleton

    The Atalante X self-balancing exoskeleton is designed to support patients. The device enables patients to stand upright safely, to perform short steps (EarlyGait) or longer steps (RealGait), and to walk either in passive mode (with full assistance) or in active mode (with partial assistance depending on patient capacity). Sessions are delivered 2 to 3 times per week for up to 2 weeks or until ICU discharge. Each session starts with standing and progressively increases in intensity, with parameters such as duration, number of steps, verticalization time, and assistance level recorded. Training is conducted by certified staff, with the primary objective of evaluating safety and feasibility, and secondary outcomes including usability and preliminary effectiveness.

    Device: Self-balancing robotic exoskeleton (Atalante X)

Interventions

  • DeviceSelf-balancing robotic exoskeleton (Atalante X)

    This intervention consists of early mobilization sessions using the Atalante X, a self-balancing robotic exoskeleton (Wandercraft). Unlike other exoskeletons that require external support or crutches, this device is fully self-stabilizing and allows patients to stand and walk hands-free. It provides both passive and active modes, enabling short steps (EarlyGait) and longer steps (RealGait), with adjustable levels of assistance tailored to each patient's capacity. Sessions are performed 2-3 times per week for up to 2 weeks or until ICU discharge.

06

What researchers measure

Primary outcomes

  1. Incidence of device- and procedure-related adverse events during exoskeleton use in ICU patients

    Safety will be assessed by the rate and type of device- and procedure-related adverse events during exoskeleton use. This includes skin lesions, catheter dislodgement, hemodynamic instability, falls, or any serious adverse events (SAEs or SADEs). An acceptable rate is defined as \<15% overall and \<15% for skin lesions.

    Time frame: Baseline and through study completion, an average of 2 weeks

Secondary outcomes

  1. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Compliance Measure Description: Compliance (%) = (number of completed exoskeleton sessions ÷ number of expected sessions) × 100. Expected sessions are fixed at 2 per week during the ICU stay. Sessions beyond 2 per week count as completed sessions but do not increase the expected total. Unit of Measure: percent (%)

    Time frame: At each training session through study completion (average of 2 weeks)

  2. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Session Duration Measure Description: Duration of each exoskeleton session; mean duration per participant across all sessions. Unit of Measure: minutes

    Time frame: At each training session through study completion (average of 2 weeks)

  3. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Total Steps per Session Measure Description: Number of steps completed during each exoskeleton session; mean steps per participant across sessions. Unit of Measure: steps

    Time frame: At each training session through study completion (average of 2 weeks)

  4. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Duration by Walking Mode Measure Description: Time spent in each walking mode during exoskeleton sessions. EarlyGait and RealGait are reported separately; for each mode, the participant's mean duration across sessions is calculated. Unit of Measure: minutes

    Time frame: At each training session through study completion (average of 2 weeks)

  5. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Steps by Walking Mode Measure Description: Number of steps performed in each walking mode during exoskeleton sessions. EarlyGait and RealGait are reported separately; for each mode, the participant's mean steps across sessions is calculated. Unit of Measure: steps

    Time frame: At each training session through study completion (average of 2 weeks)

  6. To evaluate the feasibility of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Lowest Assistance Level Achieved Measure Description: Lowest exoskeleton assistance (%) at which the participant completed ≥3 consecutive steps across all sessions. Unit of Measure: percent (%)

    Time frame: At each training session through study completion (average of 2 weeks)

  7. To evaluate the usability of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Donning and Doffing Time Measure Description: Time required to don and to doff the exoskeleton during each session. Donning and doffing are reported separately; for each, the participant's mean time across sessions is calculated. Unit of Measure: minutes

    Time frame: At each training session through study completion (average of 2 weeks)

  8. To evaluate the usability of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Satisfaction Score (Patient and Operator) Measure Description: Session-by-session satisfaction on a 0-10 numeric rating scale, reported by the patient and by the operator; mean per reporter (patient, operator) across sessions. Unit of Measure: score (0-10)

    Time frame: At each training session through study completion (average of 2 weeks)

  9. To evaluate the usability of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Operator Workload (NASA-TLX) Measure Description: Overall workload scored with NASA-TLX at the end of the protocol. Unit of Measure: score (0-100)

    Time frame: At study completion (average of 2 weeks)

  10. To evaluate the usability of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: System Usability Scale (SUS) Measure Description: Device usability scored with the System Usability Scale at the end of the protocol. Unit of Measure: score (0-100)

    Time frame: At study completion (average of 2 weeks)

  11. To evaluate the usability of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Operators per Session (overall and by qualification) Measure Description: Total number of operators involved per session (donning, doffing, and during training). Counts will also be reported by qualification category (PT, RN, physician, technician, other). For each participant, the mean count per session will be calculated overall and per category. Unit of Measure: count and qualification

    Time frame: At each training session through study completion (average of 2 weeks)

  12. To evaluate the effectiveness of the self-balanced exoskeleton Atalante X among patients in the intensive care unit (ICU) who have undergone thoracic surgery

    Outcome: Functional Mobility (JH-HLM) Measure Description: Johns Hopkins Highest Level of Mobility score (1-8; higher = greater mobility), assessed per JH-HLM protocol. Unit of Measure: score (1-8)

    Time frame: Baseline and at study completion (average of 2 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Feb 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 24, 2025
StartEst.
Oct 2025
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07220733
Lead sponsor
Wandercraft
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Oct 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Oct 24, 2025

Study contacts

Raghu Seethala
Contact
RSEETHALA@BWH.HARVARD.EDU
617-525-3150
Stephanie KORLE
Contact
skorle@mgb.org
918-772-0845

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion